Last reviewed · How we verify

Tacrolimus, Sandoz

University of Cincinnati · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Tacrolimus, Sandoz is a Small molecule drug developed by University of Cincinnati. It is currently FDA-approved. Also known as: Sandoz tacrolimus.

Tacrolimus, Sandoz is a small molecule inhibitor of the FK506-binding protein 1A, used to treat various transplant-related complications, including those associated with kidney and liver transplants, as well as chronic kidney insufficiency. It is classified as an INHIBITOR drug class, specifically targeting the peptidyl-prolyl cis-trans isomerase FKBP1A molecular target.

At a glance

Generic nameTacrolimus, Sandoz
Also known asSandoz tacrolimus
SponsorUniversity of Cincinnati
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Tacrolimus, Sandoz

What is Tacrolimus, Sandoz?

Tacrolimus, Sandoz is a Small molecule drug developed by University of Cincinnati.

Who makes Tacrolimus, Sandoz?

Tacrolimus, Sandoz is developed and marketed by University of Cincinnati (see full University of Cincinnati pipeline at /company/university-of-cincinnati).

Is Tacrolimus, Sandoz also known as anything else?

Tacrolimus, Sandoz is also known as Sandoz tacrolimus.

What development phase is Tacrolimus, Sandoz in?

Tacrolimus, Sandoz is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing